Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)

•The combination of vorolanib and everolimus showed promising efficacy.•Vorolanib plus everolimus was well-tolerated with manageable safety profile.•This study provided a new option for previously treated patients with metastatic renal cell carcinoma.